Endocrine Abstracts

Introduction: Prolactin-producing pituitary adenomas are the most common pituitary tumors in clinical practice. In men they are more aggressive and their response to pharmacological treatment is unknown.Objective: Describe the clinical characteristics and response according to the treatment of a group of male patients with invasive macroprolactinomas.Materials and methods: A retrospective descriptive study, a series of cases, in 30...

Introduction: A two-step approach is usually used to diagnose GDM. At 24–28 weeks of pregnancy, a 50 g 1-hour glucose or O’Sullivan test is performed. If it is positive (≥140 mg/dl), it is followed by a 100 g-3 hours-Oral Glucose Tolerance Test (OGTT) which is considered positive if at least two or more values are ≥ of reference values (105-190-165-145 mg/dl). Despite it is not include in any clinical practice guideline, sometimes the 100 g OGTT is obviat...

IntroductionDyslipidemia is a major cardiovascular risk factor, being its detection and control essential due to risk of serious complications. Numerous trials have demonstrated its relationship with T2D, but it has not been so well studied in T1D.ObjectiveTo obtain information about relationship between dyslipidemia and T1D and analyze its prevalence and control in a sample of patients.<p class="abstext"...

Glioblastoma (GBM) is the most prevalent and most lethal primary brain endocrine-related cancer (ERC) in adults which, in addition to the late-stage diagnosis and the lack of effective novel therapies, results in the low quality of life of patients and the poor prognosis, with a median survival from 10 to 14 months after diagnosis. Accordingly, the identification of novel molecular biomarkers of diagnosis and/or prognosis, as well as therapeutic targets becomes crucial to comb...

Intracranial Tumors comprise a diverse group of endocrine-related tumors [ERTs; e.g. craniopharyngiomas (CPs) and pituitary-tumors (PTs)], representing significant challenges for the diagnosis/prognosis/treatment of patients, their families and health systems due to their heterogeneity, associated neurological impairment and endocrine comorbidities. However, despite recent advances, the current treatment (e.g. surgery plus irradiation in CPs, pharmacological treatment with som...